Sanofi

Sustainable and Equitable Access to Healthcare

We strive to improve and accelerate sustainable and equitable access to quality medicines, vaccines and quality healthcare for underserved and vulnerable populations who need it most, in places where we can have the greatest impact. For more information, see our Access to Healthcare page.  

Comprehensive Care Programs for Global Health Priority Diseases

We are focused on diseases considered as global health problems, especially those worsened by climate and environmental challenges, such as respiratory diseases and diabetes, with the design of comprehensive access to care solutions that include: 

  • Awareness and Education: raising awareness and educating the society and vulnerable communities about environment and health risks, disease detection, prevention and care. 

  • Strengthening health systems: training healthcare providers and community health workers, leveraging health surveillance systems to better identify and address health disparities, and supporting sustainable ecosystems transformation. 

  • Closing the gaps in access to care: embedding healthcare services in the communities and providing more equitable healthcare solutions at an adapted price where appropriate. 

  • Policy strengthening: engaging with local authorities and other stakeholders to create enabling policy and financing environment for better disease prevention, diagnosis and management. 

We concentrate our efforts on regions with the highest disease burden, unmet needs according to several criteria, and strong political commitment to tackle these diseases. We also consider the feasibility of implementing such programs to deliver the greatest sustainable impact. Sustainable and equitable access to care is a shared responsibility involving diverse stakeholders, including health authorities, policymakers, payers, healthcare providers, and global and local organizations. By developing solutions along the patient care pathway and adapting different access models, we ensure we meet the specific needs of healthcare systems and local populations. 

AccesS Diabetes Program

Since 2023, Sanofi has strengthened its commitment to sustainable and equitable access to diabetes care in LMICs and underserved communities through a series of partnerships with local healthcare systems, care providers, and global organizations. These include Memoranda of Understanding (MoUs) with the Ministry of Health of Ghana, the Department of Health of South Africa, and the Delta and Kano States of Nigeria. 

The “AccesS Diabetes” program tackles potential barriers through multi-faceted approaches, covering awareness and screening capacity, patient support initiatives, healthcare practitioner training, and provision of analogue insulins at an adapted price.  

In Ghana 

  • Training for general practitioners (GPs) and other groups of healthcare professionals (HCPs), through a mentor-mentee program and the International Diabetes Federation (IDF) School of Diabetes. Since 2023, we have trained 250 GPs and 340 nurses, dieticians and pharmacists.  

  • In 2025, we supported the launch of the Kids and Diabetes in School (KiDS) program for diabetes prevention and education at school, reaching 6,670 children, 1,110 parents and 235 teachers in 13 schools.  

KiDS is an IDF program undertaken in partnership with the International Society of Pediatric and Adolescent Diabetes (ISPAD) and supported by an educational grant from Sanofi. Since the program inception in 2013, KiDS resources have reached over 1.3 million children and more than 33,000 teachers and school staff in 23 countries.  

Sanofi is also part of the Ghana Integrated Health Initiative (IHI) “AYA”. Launched in September 2024 in partnership with the Ghana Ministry of Health, the Gates Foundation, Sanofi, Bayer, Eli Lilly and other partners, AYA is a three-year initiative that aims to enhance non-communicable disease treatment. 

In Nigeria 

  • Sanofi, together with its partners, supports the training of different HCP groups, including GPs, nurses and pharmacists. As of end of 2025, 100 GPs and 216 HCPs have been trained. 

  • In 2025, we launched a health professional/patient digital solution that aims to improve patient education, self-management and monitoring. 

In 2025, Sanofi signed a MoU with the authorities of Kano State in Nigeria.  

Global Health Unit (GHU)

Our Global Health Unit (GHU) works to address today’s many growing healthcare challenges — with a focus on non-communicable diseases (NCDs) — through a self-sustained not-for-profit social business model. The GHU provides access to a broad portfolio of quality medicines in countries with the highest unmet medical needs and where Sanofi has little or no presence. Through local, regional and global cross-sector partners, the GHU co-creates innovative access models, supports local capacity building initiatives, and invests in innovative local entrepreneurial companies.  

The GHU's target is to reach two million people in over 40 LMIC markets to provide NCD care by 2030. At the end of 2025, and since its launch in 2021, the GHU has reached over 1,100,000 patients with NCD treatment. 

Local Healthcare System Strengthening

The GHU collaborates with local communities, authorities and non-governmental organizations to co-create and develop sustainable healthcare ecosystems for those who suffer from chronic diseases and require complex care. Through its strategic partnerships, the GHU collaborates on healthcare professional and community health worker education, strengthening supply chain operations, and optimizing facility efficiencies to ensure patients receive medicines as part of high-quality care.  

At the end of 2025, the GHU co-designed more than 100 NCD programs and reached over 4.9 million beneficiaries and over37,000 Healthcare providers.    

Impact Fund

Our Impact Investment Fund helps startups and innovators deliver scalable, sustainable healthcare solutions in underserved regions. With €25 million in funding, the Impact Investment Fund provides inclusive financing and technical assistance to small businesses, leveraging global, regional, and local investment to support improved access to medicines and healthcare at the last mile. The fund has invested $10.1 million in eight impact-driven ventures to date, contributing to more than 10 million patients indirectly reached through facilities in over 15 countries across Africa and Southeast Asia. These investments focus on innovative solutions aimed at addressing critical healthcare challenges in hard-to-reach communities.